Wang, Yucai http://orcid.org/0000-0002-1576-8341
Sinha, Sutapa
Wellik, Linda E.
Secreto, Charla R.
Rech, Karen L.
Call, Timothy G.
Parikh, Sameer A. http://orcid.org/0000-0002-3221-7314
Kenderian, Saad S. http://orcid.org/0000-0003-2767-3830
Muchtar, Eli
Hayman, Suzanne R.
Koehler, Amber B.
Van Dyke, Daniel L.
Leis, Jose F.
Slager, Susan L.
Dong, Haidong
Kay, Neil E. http://orcid.org/0000-0002-5951-5055
He, Rong
Ding, Wei http://orcid.org/0000-0001-9811-4601
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K12 CA090628, K12 CA090628)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Merck
Article History
Received: 21 February 2021
Revised: 28 March 2021
Accepted: 13 April 2021
First Online: 10 May 2021
Conflict of interest
: Y.W. reports research funding (provided to the institution) from Incyte, InnoCare, Novartis, and Genentech. S.A.P. reports funding (provided to the institution) from Pharmacyclics, Janssen, AstraZeneca, TG Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which he is a principal investigator, and participation in advisory board meetings of Pharmacyclics, AstraZeneca, Genentech, Gilead, GlaxoSmithKline, Verastem Oncology, and AbbVie (he was not personally compensated). S.S.K. acknowledges patents and royalties to Novartis, Humanigen, and Mettaforge, research funding from Kite, Gilead, Juno, Celegene, Novartis, Toledo, Humanigen, Lentigen, Morphosys, and Sunesis, and advisory board membership for Kite, Humanigen, and Juno. N.E.K. reports research funding from AbbVie, Acerta Pharma, Bristol Meyer Squibb, Celgene, MEI Pharma, Pharmacyclics, Sunesis, TG Therapeutics, Tolero Pharmaceuticals, data safety monitoring committee for Agios Pharm, AstraZeneca, Bristol Meyer Squibb-Celgene, Cytomx Therapeutics, MorphoSys, Rigel, and advisory board for AbbVie, AstraZeneca, Cytomx Therapy, Dava Oncology, Juno Therapeutics, Oncotracker, Pharmacyclics. W.D. reports research funding (provided to the institution) from Merck and DTRM, and participation in advisory board meetings of Octapharma and Alexion (she was not personally compensated).